We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Unilateral lower‐limb vasculopathy: A rare adverse event of CDK4/6 inhibitor in breast cancer.
- Authors
Chin, Chih‐Ching; Shiau, Jun‐Ping; Luo, Chi‐Wen; Hou, Ming‐Feng
- Abstract
Computed tomography (CT) revealed right axillary lymph nodes and liver metastasis, with the pathology report confirming ductal carcinoma with estrogen receptor positive (95%), progesterone receptor positive (5%), HER2 negative, and Ki-67 80%, cT4aN3M1. This rash would usually appear 1 week after initiating therapy and is correlated with the therapeutic efficacy.5 Herein, we report a rare case of severe unilateral lower-limb vasculopathy after palbociclib and letrozole use, and to our best knowledge, from a PubMed database search, this is the first report. Cyclin-dependent 4/6 kinase inhibitors (CDK4/6i) combined with aromatase inhibitor (AI) is currently recognized as first-line therapy in HR+, human epidermal growth factor receptor 2 (HER2) negative, metastatic breast cancer.1,2 Cyclin-dependent kinases (CDK) were initially discovered in the cell cycle, while many "cyclins" subunits were recognized as possessing different functions.
- Subjects
CYCLIN-dependent kinase inhibitors; HORMONE receptor positive breast cancer; ACNEIFORM eruptions; BREAST cancer; VASCULAR diseases; METASTATIC breast cancer; EPIDERMAL growth factor receptors
- Publication
Kaohsiung Journal of Medical Sciences, 2022, Vol 38, Issue 5, p494
- ISSN
1607-551X
- Publication type
Article
- DOI
10.1002/kjm2.12526